



EXPRESS MAIL CERTIFICATE

Date 12/11/01 Label No. EL 767720785 - 4S  
I hereby certify that, on the date indicated above, this paper or  
fee was deposited with the U.S. Postal Service & that it was  
addressed for delivery to the Assistant Commissioner for  
Patents, Washington, DC 20231 by "Express Mail Post Office  
to Addressee" service.

B.W. Lee B.W. Lee  
Name (Print) Signature

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR  
CREDIT ANY EXCESS IN THE FEES DUE WITH THIS  
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Customer No.:   
07278  
PATENT TRADEMARK OFFICE

Docket No.:3322/1H702 US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Joanne M. MEYER; Rory BARRINGTON-MARTIN; and  
Alexander PARKER

Serial No.: 09/935,464

Group Art Unit: 1655

Confirmation No.: 9495

Filed: August 23, 2001

Examiner: Not yet assigned

For: METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING  
NEUROPSYCHIATRIC DISORDERS SUCH AS SCHIZOPHRENIA

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of  
Patents and Trademarks  
Washington, DC 20231

Sir:

In order to comply with the duty to disclose information under 37  
C.F.R. § 1.56, Applicants submit herewith an Information Disclosure Statement in  
accordance with 37 CFR §§ 1.97 and 1.98. In particular, Applicants submit

herewith a Form PTO-1449 listing references for consideration by the Examiner.

This application is a Continuation-in-part of U.S. Patent Application Serial No.

09/757,300 filed on January 9, 2001 (hereinafter referred to as "the '300 application"). To avoid overburdening the Examiner, copies of the references cited in the accompanying Form PTO-1449 are not submitted herewith as the reference are already of record in the '300 application. However, copies of the references will be provided at the Examiner's request.

This Information Disclosure Statement is being submitted in accordance with 37 C.F.R. § 1.97(b) and before the mailing of a first Office Action on the merits. It is therefore believed that no fee is required for this submission. However, should the U.S. Patent and Trademark Office determine that any fee is required or that any refund is due for this application, the Commissioner is authorized and requested to charge any required fee(s) and/or credit any refund(s) due to Deposit Account No. 04-0100.


It is requested that each document cited (including any reference or other document cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration by the Examiner, and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason. This

is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed. Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: December 17, 2001

  
\_\_\_\_\_  
Samuel S. Woodley, Ph.D.  
Registration No. 43,287  
Agent for Applicant

**DARBY & DARBY**  
805 Third Avenue  
New York, NY 10022  
(212) 527-7700

DEC 17 2001

JCSA

PATENT &amp; TRADEMARK OFFICE

**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 3322/1H702 US1      SERIAL NO: 09/935,464  
 APPLICANT: Joanne M. MEYER et al.      FILING DATE: August 23, 2001

**U.S. PATENT DOCUMENTS**

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
	1. 5,474,796	12/12/95	Brennan	427	21.3	5/27/93


**FOREIGN PATENT DOCUMENTS**

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION YES</u>	<u>NO</u>
---------------------------	------------------------	-------------	----------------	--------------	-----------------	------------------------	-----------

**OTHER REFERENCES**  
**(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)**

\*EXAMINER INITIALS

2. Lih-Shen Chin et al., "Impairment of axonal development and of synaptogenesis in hippocampal neurons of synapsin I-deficient mice," *Proc. Natl. Acad. Sci. USA*, September 1995, Vol. 92, pages 9230-9234
3. Simon A. Hawley et al., "5'-AMP Activates the AMP-activated Protein Kinase Cascade, and  $Ca^{2+}$ /Calmodulin Activates the Calmodulin-dependent Protein Kinase I Cascade, via Three Independent Mechanism," *The Journal of Biological Chemistry*, November 1995, Vol. 270, No. 45, pages 27186-27191
4. Lian Li et al., "Impairment of synaptic vesicle clustering and of synaptic transmission, and increased seizure propensity, in synapsin I-deficient mice," *Proc. Natl. Acad. Sci. USA*, September 1995, Vol. 92, pages 9235-9239
5. Peter McGuffin et al., "Genetic basis of schizophrenia," *The Lancet*, September 9, 1995, Vol. 346, pages 678-682

**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 3322/1H702 US1      SERIAL NO: 09/935,464  
APPLICANT: Joanne M. MEYER et al.      FILING DATE: August 23, 2001

\*EXAMINER  
INITIALS

Hisayuki Yokokura et al., "Isolation and comparison of rat cDNAs encoding Ca<sup>2+</sup>/calmodulin-dependent protein kinase I isoforms," *Biochimica et Biophysica Acta*, 1997, pages 8-12

6. D. Grafham, "Direct Submission," GenBank Accession No. AL023754.1 (GI: 4007152) (November 23, 1999; submitted November 27, 1998)
7. Hillier et al., "The WashU-Merck EST Project," GenBank Accession No. R05661 (GI: 756281) (Entry Created:April 3, 1995; Last Updated: April 3, 1995)
8. H. Bloecker et al., "EST," GenBank Accession No. AL134342 (GI: 6602529) (Entry Created: December 20, 1999; Last Updated: February 25, 2000)
9. D. Grafham, "Direct Submission," GenBank Accession No. CAA19296.1 (GI: 4007153) (November 23, 1999; submitted November 27, 1998)
10. S. Rhodes, "Direct Submission," GenBank Accession NO. AL049688.1 (GI: 4678721) (April 21, 1999; submitted April 21, 1999).

EXAMINER: \_\_\_\_\_

DATE CONSIDERED: \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.